AR126154A1 - Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 - Google Patents
Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3Info
- Publication number
- AR126154A1 AR126154A1 ARP220101578A ARP220101578A AR126154A1 AR 126154 A1 AR126154 A1 AR 126154A1 AR P220101578 A ARP220101578 A AR P220101578A AR P220101578 A ARP220101578 A AR P220101578A AR 126154 A1 AR126154 A1 AR 126154A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide chain
- specificity
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 10
- 229920001184 polypeptide Polymers 0.000 abstract 22
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 22
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 22
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 9
- 108060003951 Immunoglobulin Proteins 0.000 abstract 6
- 102000018358 immunoglobulin Human genes 0.000 abstract 6
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 102100040835 Claudin-18 Human genes 0.000 abstract 1
- 101000749329 Homo sapiens Claudin-18 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona agentes de unión que comprenden al menos dos dominios de unión, donde un primer dominio de unión tiene especificidad para CLDN18.2 y un segundo dominio de unión tiene especificidad para CD3, y métodos para el uso de estos agentes de unión o ácidos nucleicos que los codifican para el tratamiento del cáncer. Un agente de unión caracterizado porque comprende un dominio de unión con especificidad para CLDN18.2 y un dominio de unión con especificidad para CD3, donde el agente de unión comprende al menos tres cadenas de polipéptidos, donde (I) una primera cadena de polipéptidos comprende una región variable de una cadena pesada (VH) derivada de una inmunoglobulina con especificidad para CLDN18.2 (VH(CLDN18.2)), (II) una segunda cadena de polipéptidos comprende una VH derivada de una inmunoglobulina con especificidad para CD3 (VH(CD3)) y una región variable de una cadena ligera (VL) derivada de una inmunoglobulina con especificidad para CD3 (VL(CD3)), y (III) una tercera cadena de polipéptidos comprende una VL derivada de una inmunoglobulina con especificidad para CLDN18.2 (VL(CLDN18.2)). Un agente de unión caracterizado porque comprende un dominio de unión con especificidad para CLDN18.2 que comprende una región variable de una cadena pesada (VH) derivada de una inmunoglobulina con especificidad para CLDN18.2 (VH(CLDN18.2)) y una región variable de una cadena ligera (VL) derivada de una inmunoglobulina con especificidad para CLDN18.2 (VL(CLDN18.2)), donde la VH(CLDN18.2) comprende a CDR1 que comprende la secuencia de aminoácidos SYWIN (SEQ ID Nº 32), un CDR2 que comprende la secuencia de aminoácidos NIYPSDSYTNYNQKFQG (SEQ ID Nº 33), y un CDR3 que comprende la secuencia de aminoácidos SWRGNSFDY (SEQ ID Nº 34) y la VL(CLDN18.2) comprende a CDR1 que comprende la secuencia de aminoácidos KSSQSLLNSGNQKNYLT (SEQ ID Nº 35), un CDR2 que comprende la secuencia de aminoácidos WASTRES (SEQ ID Nº 36), y un CDR3 que comprende la secuencia de aminoácidos QNDYSYPFT (SEQ ID Nº 37). Un agente de unión caracterizado porque comprende dos dominios de unión con especificidad para CLDN18.2 y un dominio de unión con especificidad para CD3, donde el agente de unión comprende cuatro cadenas de polipéptidos, donde (I) la primera cadena de polipéptidos comprende o consiste en una secuencia de aminoácidos representada por la SEQ ID Nº 73, (II) la segunda cadena polipeptídica comprende o consiste en una secuencia de aminoácidos representada por la SEQ ID Nº 74, (III) la tercera cadena polipeptídica comprende o consiste en una secuencia de aminoácidos representada por la SEQ ID Nº 78 y (IV) la cuarta cadena de polipéptidos es idéntica a la tercera cadena de polipéptidos, donde la primera cadena de polipéptidos interactúa con la segunda cadena de polipéptidos y con la tercera cadena de polipéptidos, y la segunda cadena de polipéptidos interactúa con la cuarta cadena de polipéptidos. Un agente de unión caracterizado porque comprende un dominio de unión con especificidad para CLDN18.2 y un dominio de unión con especificidad para CD3, donde el agente de unión comprende tres cadenas de polipéptidos, donde (I) la primera cadena de polipéptidos comprende o consiste en una secuencia de aminoácidos representada por la SEQ ID Nº 73, (II) la segunda cadena polipeptídica comprende o consiste en una secuencia de aminoácidos representada por la SEQ ID Nº 75 y (III) la tercera cadena polipeptídica comprende o consiste en una secuencia de aminoácidos representada por la SEQ ID Nº 78, donde la primera cadena de polipéptidos interactúa con la segunda cadena de polipéptidos y con la tercera cadena de polipéptidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/066141 WO2022262959A1 (en) | 2021-06-15 | 2021-06-15 | Bispecific binding agents binding to cldn18.2 and cd3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126154A1 true AR126154A1 (es) | 2023-09-13 |
Family
ID=77519090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101578A AR126154A1 (es) | 2021-06-15 | 2022-06-15 | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11739145B2 (es) |
| EP (1) | EP4355428A1 (es) |
| JP (2) | JP7513854B2 (es) |
| KR (1) | KR20240032847A (es) |
| CN (1) | CN117858906A (es) |
| AR (1) | AR126154A1 (es) |
| AU (1) | AU2022292895A1 (es) |
| BR (1) | BR112023026566A2 (es) |
| CA (1) | CA3222300A1 (es) |
| CL (1) | CL2023003725A1 (es) |
| CO (1) | CO2023017378A2 (es) |
| IL (1) | IL308072A (es) |
| MX (1) | MX2023014666A (es) |
| TW (1) | TW202317624A (es) |
| WO (2) | WO2022262959A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024126457A1 (en) * | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| MXPA05004022A (es) | 2002-10-17 | 2005-10-05 | Genmab As | Anticuerpos monoclonales humanos contra cd20. |
| EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| SG11201407190TA (en) | 2012-05-15 | 2014-12-30 | Bristol Myers Squibb Co | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US10738132B2 (en) | 2013-01-14 | 2020-08-11 | Xencor, Inc. | Heterodimeric proteins |
| CN110894240B (zh) * | 2014-11-26 | 2022-04-15 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CN111518214B (zh) * | 2019-02-03 | 2023-09-22 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的双特异性抗体及其制备方法和应用 |
| SG11202100987RA (en) | 2018-08-03 | 2021-02-25 | Amgen Res Munich Gmbh | Antibody constructs for cldn18.2 and cd3 |
| CN115916819A (zh) * | 2020-05-29 | 2023-04-04 | 武汉友芝友生物制药股份有限公司 | 抗cldn18.2和cd3的双特异性抗体 |
-
2021
- 2021-06-15 WO PCT/EP2021/066141 patent/WO2022262959A1/en active Application Filing
-
2022
- 2022-06-15 KR KR1020247001571A patent/KR20240032847A/ko unknown
- 2022-06-15 CN CN202280042413.9A patent/CN117858906A/zh active Pending
- 2022-06-15 CA CA3222300A patent/CA3222300A1/en active Pending
- 2022-06-15 JP JP2023577405A patent/JP7513854B2/ja active Active
- 2022-06-15 AU AU2022292895A patent/AU2022292895A1/en active Pending
- 2022-06-15 MX MX2023014666A patent/MX2023014666A/es unknown
- 2022-06-15 WO PCT/EP2022/066299 patent/WO2022263508A1/en active Application Filing
- 2022-06-15 EP EP22750661.5A patent/EP4355428A1/en active Pending
- 2022-06-15 TW TW111122151A patent/TW202317624A/zh unknown
- 2022-06-15 AR ARP220101578A patent/AR126154A1/es unknown
- 2022-06-15 BR BR112023026566A patent/BR112023026566A2/pt unknown
- 2022-06-15 IL IL308072A patent/IL308072A/en unknown
- 2022-12-06 US US18/062,465 patent/US11739145B2/en active Active
-
2023
- 2023-07-05 US US18/347,361 patent/US20240018234A1/en active Pending
- 2023-12-13 CL CL2023003725A patent/CL2023003725A1/es unknown
- 2023-12-14 CO CONC2023/0017378A patent/CO2023017378A2/es unknown
-
2024
- 2024-06-10 JP JP2024093451A patent/JP2024116283A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022262959A1 (en) | 2022-12-22 |
| EP4355428A1 (en) | 2024-04-24 |
| CA3222300A1 (en) | 2022-12-22 |
| CL2023003725A1 (es) | 2024-05-17 |
| US11739145B2 (en) | 2023-08-29 |
| IL308072A (en) | 2023-12-01 |
| CO2023017378A2 (es) | 2024-02-05 |
| CN117858906A (zh) | 2024-04-09 |
| JP2024116283A (ja) | 2024-08-27 |
| JP7513854B2 (ja) | 2024-07-09 |
| BR112023026566A2 (pt) | 2024-03-05 |
| JP2024520868A (ja) | 2024-05-24 |
| KR20240032847A (ko) | 2024-03-12 |
| WO2022263508A1 (en) | 2022-12-22 |
| AU2022292895A1 (en) | 2024-01-04 |
| US20240018234A1 (en) | 2024-01-18 |
| US20230137677A1 (en) | 2023-05-04 |
| MX2023014666A (es) | 2024-01-12 |
| TW202317624A (zh) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117727A1 (es) | Anticuerpos que se unen a cd3 | |
| AR110979A1 (es) | Moléculas de unión a cd70 y métodos de uso de las mismas | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| BR112019008859A2 (pt) | anticorpos direcionados contra a morte programada 1 (pd-1) | |
| PE20230160A1 (es) | Anticuerpos especificos para cd47, pd-l1 y sus usos | |
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR084141A1 (es) | Anticuerpos neutralizadores anti-ccl20 | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| AR126154A1 (es) | Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3 | |
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| AR105938A1 (es) | Anticuerpo anti-epha4 | |
| BR112018072140A2 (pt) | anticorpos anti-basigin humanizados e uso dos mesmos | |
| AR124289A1 (es) | Composiciones de agentes de unión a antígenos de guanilato ciclasa c (gcc) y métodos de uso de estos | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| AR125488A1 (es) | Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas | |
| ZA202305217B (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| PE20180498A1 (es) | Inmunoglobulinas conjugadas en cys80 | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| AR087485A1 (es) | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc |